Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Wednesday, 9 June 2021, 11:31 JST

Source: Eisai

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).

Eisai considers neurology a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

For more information, visit https://www.eisai.com/news/2021/news202143.html.

Topic: Press release summary
Source: Eisai
Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network

Eisai Related News

Friday, 27 March 2026, 20:14 JST

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

Friday, 27 March 2026, 18:19 JST

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Monday, 23 March 2026, 11:19 JST

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026

Thursday, 19 March 2026, 10:54 JST

Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)

Tuesday, 17 March 2026, 19:49 JST

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation

More news >>


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575